Eli Historical Cash Flow
| LLY Stock | USD 733.51 8.64 1.19% |
Analysis of Eli Lilly cash flow over time is an excellent tool to project Eli Lilly future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 1 B or Other Non Cash Items of 2.4 B as it is a great indicator of Eli Lilly ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Eli Lilly latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eli Lilly is a good buy for the upcoming year.
Eli |
About Eli Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Eli balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Eli's non-liquid assets can be easily converted into cash.
Eli Lilly Cash Flow Chart
Eli Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Eli Lilly Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Eli Lilly's Change In Cash is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 3.4 B in 2024, whereas Sale Purchase Of Stock is likely to drop (787.5 M) in 2024. Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Eli Lilly to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Eli Lilly operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Eli Lilly's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Eli Lilly's Change In Cash is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 3.4 B in 2024, whereas Sale Purchase Of Stock is likely to drop (787.5 M) in 2024.
Eli Lilly cash flow statement Correlations
Click cells to compare fundamentals
Eli Lilly Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eli Lilly cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | (4.4B) | (500M) | (1.3B) | (1.5B) | (750M) | (787.5M) | |
| Change To Inventory | (258.7M) | (533.4M) | (235.9M) | (599.7M) | (1.4B) | (1.4B) | |
| Change In Cash | (5.7B) | 1.3B | 161.4M | (1.8B) | 751.6M | 789.2M | |
| Free Cash Flow | 3.5B | 4.5B | 5.4B | 4.6B | (3.2B) | (3.0B) | |
| Change In Working Capital | (1.7B) | (747.4M) | (1.0B) | (14.5M) | (3.1B) | (2.9B) | |
| Begin Period Cash Flow | 8.0B | 2.3B | 3.7B | 3.8B | 2.1B | 3.4B | |
| Other Cashflows From Financing Activities | (200.1M) | (241.6M) | (295.9M) | 1.2B | 25.6B | 26.9B | |
| Depreciation | 1.2B | 1.3B | 1.5B | 1.5B | 1.5B | 1.0B | |
| Other Non Cash Items | (3.4B) | (444.2M) | 1.6B | 1.1B | 2.2B | 2.4B | |
| Dividends Paid | 2.4B | 2.7B | 3.1B | 3.5B | (4.1B) | (3.9B) | |
| Capital Expenditures | 1.4B | 2.0B | 1.9B | 2.5B | 7.4B | 7.8B | |
| Total Cash From Operating Activities | 4.8B | 6.5B | 7.3B | 7.1B | 4.2B | 4.3B | |
| Net Income | 8.3B | 6.2B | 5.6B | 6.2B | 5.2B | 3.1B | |
| Total Cash From Financing Activities | (2.3B) | (3.1B) | (4.1B) | (5.4B) | 3.5B | 3.7B | |
| End Period Cash Flow | 2.3B | 3.7B | 3.8B | 2.1B | 2.8B | 3.4B | |
| Stock Based Compensation | 312.4M | 308.1M | 342.8M | 371.1M | 628.5M | 334.2M | |
| Change To Account Receivables | (127.2M) | (1.4B) | (1.3B) | (299.6M) | (2.5B) | (2.6B) | |
| Total Cashflows From Investing Activities | (8.1B) | (2.3B) | (2.9B) | (3.8B) | (7.2B) | (6.8B) | |
| Other Cashflows From Investing Activities | (7.5B) | 102.8M | 24.3M | (1.2B) | (1.0B) | (1.1B) | |
| Investments | 456.2M | 516.7M | (166M) | (244M) | (7.2B) | (6.8B) | |
| Change Receivables | (357M) | (996.7M) | (127.2M) | (299.6M) | (269.6M) | (283.1M) | |
| Net Borrowings | 4.7B | 291.6M | 501.4M | (62M) | (71.3M) | (67.7M) | |
| Cash And Cash Equivalents Changes | 2.0B | 1.5B | (5.7B) | (1.6B) | (1.4B) | (1.4B) | |
| Cash Flows Other Operating | (590.1M) | (980M) | (602.3M) | (793.5M) | (714.2M) | (678.4M) | |
| Change To Netincome | 653.3M | (270.6M) | 1.2B | (668.4M) | (601.6M) | (571.5M) | |
| Change To Liabilities | (699M) | 1.3B | (664.1M) | 1.7B | 1.9B | 2.0B | |
| Change To Operating Activities | (602.3M) | (457.1M) | 1.5B | (793.5M) | (714.2M) | (678.4M) |
Eli Lilly Investors Sentiment
The influence of Eli Lilly's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Eli. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Eli Lilly's public news can be used to forecast risks associated with an investment in Eli. The trend in average sentiment can be used to explain how an investor holding Eli can time the market purely based on public headlines and social activities around Eli Lilly and. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Eli Lilly's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Eli Lilly's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Eli Lilly's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Eli Lilly.
Eli Lilly Implied Volatility | 56.74 |
Eli Lilly's implied volatility exposes the market's sentiment of Eli Lilly and stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Eli Lilly's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Eli Lilly stock will not fluctuate a lot when Eli Lilly's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.79 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.